TY - JOUR T1 - Effect of photobiomodulation on reduction of CD4STAT4 and CD4IFN-? and increased treg cells and IL-10 in an experimental model of COPD JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2019.PA2035 VL - 54 IS - suppl 63 SP - PA2035 AU - Auriléia Aparecida De Brito Léia AU - Tawany Gonçalvez Santos AU - Karine Zanella Herculano AU - Nicole Cristine Rigonato-Oliveira AU - Renata Kelly Palma AU - Adriana Lino Dos Santos Franco AU - Kristianne Porta Santos Fernandes AU - Cristiano Rodrigo Alvarenga-Nascimento AU - Ana Paula Ligeiro-Oliveira Y1 - 2019/09/28 UR - http://erj.ersjournals.com/content/54/suppl_63/PA2035.abstract N2 - Currently, COPD has a high impact on morbidity and mortality worldwide. The smoking habit, smoking history, airflow rate, obstruction and pulmonary emphysema are all related to the increase in CD8+ cells and/or CD8+/CD4+ ratio, the number of these CD4+, CD8+ cells express NF-κB, STAT4, IFN-γ and perforin. A deficiency in T cells regulating CD4+CD25+Foxp3+ (Tregs) may impair the tolerance of the immune system and thus lead to immune disease. Thus, immunotherapeutic strategies, such as photobiomodulation (PBM), aim to regulate the levels of cytokines, chemokines and transcription factors. In this sense, the objective was to evaluate Foxp3 Treg cells as well as the production of IL10 in the lung after PBM in COPD model. We studied some parameters in C57BL/6 with COPD submitted to diode laser therapy (660nm, 30mW, 180s) for 15 days. The protocol used for the induction of COPD consisted in the application orotracheal of extract of cigarette smoke (3x per week/7 weeks). Bronchoalveolar lavage (BAL) and lungs were collected for analysis. Data were submitted to the One-way ANOVA test followed by the Newman-Keuls test. Significance levels adjusted to 5% (p<0.05). PBM reduced the number of inflammatory cells, the levels of IL1-β, TNF-α, IL-6, IFN-γ, MCP-1, GM-CSF (p<0,001), KC/CXCL1, LTB4 (p<0,01) and increased IL-10 (p<0,001). We also observed decrease of collagen, mucus, bronchoconstriction index, alveolar enlargement, CD4+, CD8+, CD4+STAT4+ and CD4+IFN-γ+. There was increased CD4+CD25+Foxp3+ and CD4+IL-10+. Thus, PBM can be used as immunotherapeutic strategy for the treatment of COPD through the possible mechanism of CD4+CD25+Foxp3+ e CD4+IL-10+.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA2035.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -